Physician profile
Anne M Sutherland
NPI 1609824051
$1,642.69
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $570.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $227.79 | 2019-2020 | |
| Pfizer INC. | $225.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $105.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $84.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $78.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.04 | 2019-2020 | |
| Amgen INC. | $57.95 | 2020 | |
| Novo Nordisk INC | $51.11 | 2019-2020 | |
| Antares Pharma, INC. | $45.57 | 2019-2020 | |
| Allergan, INC. | $43.32 | 2019-2020 | |
| Sanofi Pasteur INC. | $42.67 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.11 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $35.42 | 2020 | |
| Jazz Pharmaceuticals INC. | $34.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.31 | 2019-2020 | |
| Philips North America LLC | $20.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.53 | 2019 | |
| Therapeuticsmd, INC. | $18.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.98 | 2019 | |
| Eisai INC. | $14.56 | 2020 | |
| Hikma Pharmaceuticals USA | $14.52 | 2019 | |
| Biodelivery Sciences International, INC. | $11.50 | 2019 | |
| Circassia INC. | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.